Boryung Past Earnings Performance
Past criteria checks 5/6
Boryung has been growing earnings at an average annual rate of 12.7%, while the Pharmaceuticals industry saw earnings growing at 8.1% annually. Revenues have been growing at an average rate of 13.6% per year. Boryung's return on equity is 10.3%, and it has net margins of 6.3%.
Key information
12.7%
Earnings growth rate
8.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 13.6% |
| Return on equity | 10.3% |
| Net Margin | 6.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Boryung (KRX:003850) Is Taking Some Risk With Its Debt
Sep 20
Earnings Not Telling The Story For Boryung Corporation (KRX:003850)
Aug 05Why We're Not Concerned About Boryung Corporation's (KRX:003850) Share Price
Apr 06A Look At The Fair Value Of Boryung Pharmaceutical Co., Ltd. (KRX:003850)
Apr 28Boryung Pharmaceutical (KRX:003850) Has A Pretty Healthy Balance Sheet
Mar 17Here's How We Evaluate Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Dividend
Feb 27Is Boryung Pharmaceutical Co., Ltd.'s (KRX:003850) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 09Do Institutions Own Boryung Pharmaceutical Co., Ltd. (KRX:003850) Shares?
Jan 25Should You Use Boryung Pharmaceutical's (KRX:003850) Statutory Earnings To Analyse It?
Jan 10
If You Had Bought Boryung Pharmaceutical (KRX:003850) Shares Three Years Ago You'd Have Earned 122% Returns
Dec 23Is Boryung Pharmaceutical (KRX:003850) A Risky Investment?
Dec 08Would Boryung Pharmaceutical Co., Ltd. (KRX:003850) Be Valuable To Income Investors?
Nov 23Revenue & Expenses Breakdown
How Boryung makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 991,430 | 61,995 | 230,060 | 53,328 |
| 30 Jun 24 | 928,718 | 64,579 | 223,422 | 52,073 |
| 31 Mar 24 | 889,416 | 52,254 | 220,641 | 50,585 |
| 31 Dec 23 | 859,626 | 40,203 | 214,854 | 47,286 |
| 30 Sep 23 | 829,854 | 28,267 | 201,656 | 41,603 |
| 30 Jun 23 | 819,463 | 38,284 | 200,154 | 41,415 |
| 31 Mar 23 | 785,679 | 42,063 | 195,427 | 40,249 |
| 31 Dec 22 | 760,476 | 41,894 | 191,858 | 41,705 |
| 30 Sep 22 | 724,659 | 53,911 | 184,422 | 43,444 |
| 30 Jun 22 | 694,170 | 52,524 | 178,676 | 41,373 |
| 31 Mar 22 | 661,948 | 34,380 | 173,972 | 40,604 |
| 31 Dec 21 | 627,279 | 43,044 | 171,818 | 39,146 |
| 30 Sep 21 | 600,008 | 41,823 | 167,985 | 36,053 |
| 30 Jun 21 | 587,350 | 28,892 | 167,011 | 35,884 |
| 31 Mar 21 | 571,594 | 38,370 | 159,083 | 36,957 |
| 31 Dec 20 | 561,867 | 26,856 | 148,224 | 35,506 |
| 30 Sep 20 | 562,433 | 27,744 | 144,704 | 36,253 |
| 30 Jun 20 | 546,974 | 27,969 | 140,383 | 39,247 |
| 31 Mar 20 | 539,742 | 31,678 | 140,141 | 36,934 |
| 31 Dec 19 | 524,269 | 32,222 | 139,544 | 37,864 |
| 30 Sep 19 | 498,006 | 32,950 | 127,560 | 36,683 |
| 30 Jun 19 | 480,242 | 29,886 | 124,855 | 34,458 |
| 31 Mar 19 | 467,445 | 22,830 | 125,221 | 35,580 |
| 31 Dec 18 | 460,402 | 20,307 | 122,204 | 34,433 |
| 30 Sep 18 | 441,580 | 64,630 | 107,695 | 58,302 |
| 30 Jun 18 | 440,087 | 62,855 | 115,359 | 49,298 |
| 31 Mar 18 | 434,565 | 60,451 | 127,963 | 32,997 |
| 31 Dec 17 | 422,721 | 56,699 | 127,666 | 32,277 |
| 30 Sep 17 | 426,554 | -3,202 | 145,023 | 7,366 |
| 30 Jun 17 | 423,777 | -2,977 | 137,328 | 14,638 |
| 31 Mar 17 | 420,133 | 5,020 | 120,819 | 29,164 |
| 31 Dec 16 | 409,140 | 5,614 | 121,778 | 28,963 |
Quality Earnings: A003850 has high quality earnings.
Growing Profit Margin: A003850's current net profit margins (6.3%) are higher than last year (3.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A003850's earnings have grown by 12.7% per year over the past 5 years.
Accelerating Growth: A003850's earnings growth over the past year (119.3%) exceeds its 5-year average (12.7% per year).
Earnings vs Industry: A003850 earnings growth over the past year (119.3%) exceeded the Pharmaceuticals industry 22.3%.
Return on Equity
High ROE: A003850's Return on Equity (10.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 08:03 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Boryung Corporation is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Myung Sun Lee | DB Financial Investment Co. Ltd. |
| Hyung Soo Kim | Hanwha Investment & Securities Co., Ltd. |